SG11201407400XA - V1a receptor agonists - Google Patents
V1a receptor agonistsInfo
- Publication number
- SG11201407400XA SG11201407400XA SG11201407400XA SG11201407400XA SG11201407400XA SG 11201407400X A SG11201407400X A SG 11201407400XA SG 11201407400X A SG11201407400X A SG 11201407400XA SG 11201407400X A SG11201407400X A SG 11201407400XA SG 11201407400X A SG11201407400X A SG 11201407400XA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- international
- llll
- california
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date ^ ^ WO 2013/170077 A2 14 November 2013 (14.11.2013) WIPO I PCT (51) International Patent Classification: A61K38/12 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/040414 9 May 2013 (09.05.2013) English English (30) Priority Data: 61/645,558 10 May 2012 (10.05.2012) US (71) Applicant: FERRING B.V. [NL/NL]; Polaris Avenue 144, NL-2132 JX Hoofddorp (NL). (72) Inventor; and (71) Applicant : WISNIEWSKI, Kazimierz [US/US]; 8274 Chandler Hill Court, San Diego, California 92127 (US). (72) Inventors: HARRIS, Geoffrey S.; 2248 Oxford Ave., Cardiff, California 92007 (US). GAL YE AN, Robert Fe lix; 19692 Kingsley Cove Place, Cottonwood, California 96022 (US). (74) Agent: PHILLIPS, Eiflon; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, [Continued on next page] (54) Title: VIA RECEPTOR AGONISTS CJ l> l> o o i> 0<_NH 2 /T o ( ° .3^ NH O NH 2 (I) i-H o CJ o & [Continued on next page] WO 2013/170077 A2 I lllll llllllll II llllll lllll III lllll III III III lllll lllll lllll lllll lllll llll lllllll llll llll llll Published: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) (57) Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are use ful as Via vasopressin agonists, for the treatment of, e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and re - fractory ascites.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645558P | 2012-05-10 | 2012-05-10 | |
| PCT/US2013/040414 WO2013170077A2 (en) | 2012-05-10 | 2013-05-09 | V1a receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407400XA true SG11201407400XA (en) | 2014-12-30 |
Family
ID=48652296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407400XA SG11201407400XA (en) | 2012-05-10 | 2013-05-09 | V1a receptor agonists |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9644000B2 (en) |
| EP (1) | EP2847210B1 (en) |
| JP (1) | JP6231554B2 (en) |
| KR (1) | KR102050356B1 (en) |
| CN (1) | CN104350065B (en) |
| AR (1) | AR091013A1 (en) |
| AU (1) | AU2013259393B2 (en) |
| BR (1) | BR112014027996B1 (en) |
| CA (1) | CA2871776C (en) |
| DK (1) | DK2847210T3 (en) |
| ES (1) | ES2571928T3 (en) |
| HK (1) | HK1205706A1 (en) |
| HR (1) | HRP20160468T1 (en) |
| HU (1) | HUE027519T2 (en) |
| IL (1) | IL235558A (en) |
| JO (1) | JO3109B1 (en) |
| MX (1) | MX353864B (en) |
| MY (1) | MY167248A (en) |
| NZ (1) | NZ701365A (en) |
| PH (1) | PH12014502510A1 (en) |
| PL (1) | PL2847210T3 (en) |
| RS (1) | RS54722B1 (en) |
| RU (1) | RU2634617C2 (en) |
| SA (1) | SA113340536B1 (en) |
| SG (1) | SG11201407400XA (en) |
| SI (1) | SI2847210T1 (en) |
| TW (1) | TWI632161B (en) |
| WO (1) | WO2013170077A2 (en) |
| ZA (1) | ZA201408172B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9388214B2 (en) | 2014-11-05 | 2016-07-12 | Ferring B.V. | V1A receptor agonists |
| JP2017014206A (en) | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス，インコーポレイテッド | Treatment of ascites |
| JP2019525947A (en) | 2016-06-01 | 2019-09-12 | エムスリー・バイオテクノロジー・インコーポレイテッドＭ３ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | Compound |
| CN109010795B (en) * | 2018-09-12 | 2021-10-22 | 南京康舟医药科技有限公司 | Terlipressin acetate injection and preparation method thereof |
| EP4182021A2 (en) * | 2020-07-17 | 2023-05-24 | Pharmain Corporation | V1a receptor partial agonist and method of use |
| WO2023183339A1 (en) * | 2022-03-22 | 2023-09-28 | Ocelot Bio, Inc. | Selective vasopressin receptor agonist for end-stage liver disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0204278A2 (en) * | 1999-11-04 | 2003-04-28 | Ortho-Mcneil Pharmaceutical, Inc. | Nonpeptide substituted benzothiazepines as vasopressin antagonists, process for their preparation, pharmaceutical compositions containing them and their use |
| EP1188443A1 (en) * | 2000-09-15 | 2002-03-20 | Ferring BV | Improved protocol for paracentesis |
| JO2937B1 (en) * | 2004-08-11 | 2016-03-15 | فيرينغ.بي.في | Peptidic Vasopressin Receptor Agonists |
| CN101253164B (en) * | 2005-07-14 | 2012-05-16 | 弗·哈夫曼-拉罗切有限公司 | Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists |
| CA2623715A1 (en) * | 2005-09-28 | 2007-04-12 | F. Hoffmann-La Roche Ag | Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists |
| WO2007144768A2 (en) * | 2006-02-13 | 2007-12-21 | Ferring B.V. | Use of peptidic vasopressin receptor agonists |
| US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
-
2013
- 2013-04-24 JO JOP/2013/0118A patent/JO3109B1/en active
- 2013-04-30 TW TW102115416A patent/TWI632161B/en active
- 2013-05-08 SA SA113340536A patent/SA113340536B1/en unknown
- 2013-05-09 MX MX2014013646A patent/MX353864B/en active IP Right Grant
- 2013-05-09 MY MYPI2014703280A patent/MY167248A/en unknown
- 2013-05-09 SI SI201330175A patent/SI2847210T1/en unknown
- 2013-05-09 PL PL13729826T patent/PL2847210T3/en unknown
- 2013-05-09 KR KR1020147034501A patent/KR102050356B1/en active IP Right Grant
- 2013-05-09 DK DK13729826.1T patent/DK2847210T3/en active
- 2013-05-09 ES ES13729826T patent/ES2571928T3/en active Active
- 2013-05-09 EP EP13729826.1A patent/EP2847210B1/en active Active
- 2013-05-09 CN CN201380024444.2A patent/CN104350065B/en active Active
- 2013-05-09 RS RS20160293A patent/RS54722B1/en unknown
- 2013-05-09 BR BR112014027996-9A patent/BR112014027996B1/en active IP Right Grant
- 2013-05-09 CA CA2871776A patent/CA2871776C/en active Active
- 2013-05-09 JP JP2015511718A patent/JP6231554B2/en active Active
- 2013-05-09 SG SG11201407400XA patent/SG11201407400XA/en unknown
- 2013-05-09 WO PCT/US2013/040414 patent/WO2013170077A2/en active Application Filing
- 2013-05-09 HU HUE13729826A patent/HUE027519T2/en unknown
- 2013-05-09 AU AU2013259393A patent/AU2013259393B2/en active Active
- 2013-05-09 NZ NZ701365A patent/NZ701365A/en unknown
- 2013-05-09 RU RU2014143941A patent/RU2634617C2/en active
- 2013-05-09 US US14/400,282 patent/US9644000B2/en active Active
- 2013-05-10 AR ARP130101626 patent/AR091013A1/en active IP Right Grant
-
2014
- 2014-11-06 IL IL235558A patent/IL235558A/en active IP Right Grant
- 2014-11-07 ZA ZA2014/08172A patent/ZA201408172B/en unknown
- 2014-11-10 PH PH12014502510A patent/PH12014502510A1/en unknown
-
2015
- 2015-10-09 HK HK15108881.8A patent/HK1205706A1/en unknown
-
2016
- 2016-05-03 HR HRP20160468TT patent/HRP20160468T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407400XA (en) | V1a receptor agonists | |
| SG11201808625QA (en) | SOLUBLE C5aR ANTAGONISTS | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
| SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
| SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SG11201407596TA (en) | Conjugation reagents | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201407381VA (en) | System and methods for coping with doppler effects in distributed-input distributed-output wireless systems | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201808163WA (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| SG11201408133TA (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201408103XA (en) | Polyurethane-based waterproofing composition for the water-proofing of concrete structures | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions |